EMDR in Spider Phobia: Work Mechanisms and Treatment Outcome
1 other identifier
interventional
53
0 countries
N/A
Brief Summary
The goal of this study is to increase the efficiency of exposure in virtual reality (VR). Based on the EMDR research the investigators would like to show that the implementation of eye movements during the VR exposure results in a faster physiological relaxation response among probands with spider phobia, which has a positive effect on the subjective and behavioral efficacy of the VR exposure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2015
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2016
CompletedFirst Submitted
Initial submission to the registry
November 14, 2016
CompletedFirst Posted
Study publicly available on registry
November 28, 2016
CompletedNovember 28, 2016
November 1, 2016
5 months
November 14, 2016
November 21, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Change in Behavioral Assessment Test (BAT) in vivo
expected fear just before getting started and actually present fear just before finishing
5 minutes before, 5 minutes after intervention and during folow up (2 weeks post Intervention)
Secondary Outcomes (4)
Skin Conductance Reactivity (SCR)
during the VR-session
Electrocardiogram (ECG)
during the VR-session
manipulation check electrode below the right eye (M. orbicularis oculi)
during the VR- exposure sessions (5 min x 4 sessions)
Change in Subjective Fear Ratings
1 min before and during ( each minute) exposure in Virtual Reality
Study Arms (2)
Eye movements
EXPERIMENTALEye Movement Desensitization and Reprocessing Therapy + virtual reality exposure therapy
Control
ACTIVE COMPARATORvirtual reality exposure therapy
Interventions
In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, \& Renssen, 1999; de Jongh, Holmshaw, Carswell, \& van Wijk, 2011; Lapsekili \& Yelboga, 2014; Muris, Merckelbach, van Haaften, \& Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).
Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger \& Pauli, 2011).
Eligibility Criteria
You may qualify if:
- the Structured Clinical Interview for DSM-IV (SCID, First et al., 2002; applied German translation: Strukturiertes Klinisches Interview für DSM-IV, Achse I, SKID I, Wittchen et al., 1997), in order to get a reliable diagnosis of spider phobia
You may not qualify if:
- pregnancy
- current psychopharmacological medication
- current involvement in psychiatric- or psychotherapeutic treatment
- cardiovascular or neurological diseases
- color blindness
- hearing disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Phd
Study Record Dates
First Submitted
November 14, 2016
First Posted
November 28, 2016
Study Start
July 1, 2015
Primary Completion
December 1, 2015
Study Completion
September 1, 2016
Last Updated
November 28, 2016
Record last verified: 2016-11
Data Sharing
- IPD Sharing
- Will not share